Miguel Angel Rubio

Miguel Angel Rubio

Neurologist, Coordinator of ALS Multidisciplinary Unit

Dr Rubio is a clinical neurologist focused, since 2010, on neuromuscular disorders, especially in ALS and other motor neuron diseases. Aside from his clinical activity coordinating the ALS Multidisciplinary Unit, his efforts are centered on both clinical and basic research, the latter including works on mouse models (SOD1 G93A mouse) and the search for disease biomarkers in human tissue samples, in collaboration with the Group of Neuroplasticity and Regeneration (Department of Cell Biology, Physiology and Immunology, Institute of Neurosciences, Universitat Autònoma de Barcelona).

Connect
Connect trials
Active
Phase ii

RT001 in Amyotrophic Lateral Sclerosis

Industry trial

In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.

Read more
Active
Phase iii

ALXN1210-ALS-308 trial

Industry trial

This phase 3 trial aims to study the safety and efficacy of the drug ‘ravulizumab’ in people living with ALS. To register for this study, you should contact your local ALS centre or treating physician.

Read more
Active
Phase iii

VALOR study

Industry trial

Biogen is conducting a clinical trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS) with a SOD1 gene mutation.

Read more
Recruiting
Phase iii

TUDCA-ALS

Investigator initiated trial

This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.

Read more